Cathie Wood’s ARK Genomic Revolution EFT has been making big investments in the psychedelics sector since February 2022, most notably in Atai Life Sciences (NASDAQ: ATAI). The fund has now gone deeper and released an extensive report exploring “the therapeutic merits” and what the sector's investment prospects look like.

Written by research associate Pierce Jamieson, ARK’s “How ‘Far Out’ Are Psychedelic Therapeutics?” joins similar analyses by KPMG and Morgan Stanley. Together, they certainly weigh on what retail investors who are still unaware of the sector might consider a fairly good-looking market to get involved in.

The piece walks the reader through a small intro on the history of psychedelic substances then moves to a scientific review of eight related compounds and their current clinical status. It then dives into which investments pose risks and which hold opportunities in the sector. 

The information published includes average trial costs, average time span for drug development …

Full story available on Benzinga.com